Comparative analysis of adverse events requiring suspension of mTOR inhibitors: Everolimus versus sirolimus

Transplantation Proceedings

Volumn 42, Issue 8, 2010, Pages 3050-3052

  Sanchez Fructuoso A I ^a   Ruiz, J C ^b   Perez Flores I ^a   Gomez Alamillo C ^b   Calvo Romero, N ^a   Arias, M ^b  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; EVEROLIMUS; RAPAMYCIN;

ACUTE GRAFT REJECTION; ANEMIA; ARTICLE; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; GRAFT RECIPIENT; HUMAN; INFECTION; KIDNEY ALLOGRAFT; KIDNEY DYSFUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MOUTH ULCER; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RASH; TREATMENT DURATION;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 77958518592     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.07.083     Document Type: Article

References (11)

1. J.M. Morales, L. Wramner, and H. Kreis Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients Am J Transplant 2 2002 436
2. A.V. Mulay, S. Cockfield, and R. Stryker Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence Transplantation 82 2006 1153
3. W. Schuler, R. Sedrani, and S. Cottens SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo Transplantation 64 1997 36
4. E. Letavernier, and C. Legendre mToR inhibitorsinduced proteinuria: mechanisms, significance, and management Transplant Rev (Orlando) 22 2008 125
5. S. Huber, C.J. Bruns, and G. Schmid Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis Kidney Int 71 2007 771
6. N. Desai, S. Heenan, and P.S. Mortimer Sirolimus-associated lymphoedema: eight new cases and a proposed mechanism Br J Dermatol 160 2009 1322
7. A. Rodriguez-Moreno, N. Ridao, and P. Garcia-Ledesma Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center Transplant Proc 41 2009 2163
8. J.D. Morrisett, G. bdel-Fattah, and R. Hoogeveen Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients J Lipid Res 43 2002 1170
9. F.P. Schena, M.D. Pascoe, J. Alberu Sirolimus CONVERT Trial Study Group Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial Transplantation 87 2009 233
10. E. Morelon, and H. Kreis Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience Transplant Proc 35 2003 52S
11. H. Tedesco-Silva Jr, S. Vitko, J. Pascual 2306 and 2307 Study Groups 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients Transpl Int 20 2007 27